Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
The article assesses dynamics of the concentration of biomarkers of fibrosis and remodeling in the patients with stable coronary heart disease combined with chronic heart failure I–III functional class according to the NYHA classification, chronic kidney disease and type 2 diabetes against the background of therapy conducted during a year.
coronary heart disease, chronic heart failure, chronic kidney disease, type 2 diabetes, sST2, cystatin C, galectin-3
1. Belyalov F.I. Ishemicheskaya bolezn' serdca i narushenie funkcii pochek // Racional'naya farmakoterapiya v kardiologii. – 2017 – 13(3). – C. 409–415. http: //dx.doi.org/10.20996/1819-6446- 2017-13-3-409-415
2. Aimo A., Vergaro G., Passino C. et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: A meta-analysis // JACC: Heart Failure. – 2017 – 5 (4). – P. 280–286.
3. Huang Z., Zhong J., Zhang S. et al. Association between serum cystatin C and early impairment of cardiac function and structure in type 2 diabetes patients with normal renal function // Clin Cardiol. – 2022 – 45(12). – P. 1287–1296.
4. Kovalenko E.V., Markova L.I., Belaya O.L., Oranzhereeva V.N. Prognosticheskoe znachenie markerov kardial'noy disfunkcii u komorbidnyh bol'nyh s hronicheskoy serdechnoy nedostatochnost'yu // Lechaschiy vrach. – 2023 – 12 (26). – C. 15–24.
5. Oranzhereeva V.N., Belaya O.L., Kovalenko E.V. i dr. Vozmozhnosti nekotoryh sovremennyh biomarkerov v prognozirovanii neblagopriyatnyh serdechno-sosudistyh sobytiy u bol'nyh ishemicheskoy bolezn'yu serdca i hronicheskoy bolezn'yu pochek // Effektivnaya farmakoterapiya. – 2024 – 20 (31). – C. 70–75.
6. Belaya O.L., Oranzhereeva V.N., Kovalenko E.V. i dr. Biomarkery miokardial'noy i pochechnoy disfunkcii u bol'nyh ishemicheskoy bolezn'yu serdca, saharnym diabetom i hronicheskoy bolezn'yu pochek // Medicinskiy vestnik MVD. – 2023 – 125 (4). – C. 52–56.
7. Riccardi M., Myhre P.L., Zelniker T.A. et al. Soluble ST2 in Heart Failure: A Clinical Role beyond B- Type Natriuretic Peptide // J Cardiovasc Dev Dis. – 2023 – 10 (11). – P. 468 Doi:https://doi.org/10.3390/jcdd10110468
8. Belaya O.L., Ryzhkov I.M., Kovalenko E.V. i dr. Prognosticheskaya rol' biomarkera rastvorimogo ST2 v ocenke riska razvitiya neblagopriyatnyh serdechno-sosudistyh sobytiy u bol'nyh ishemicheskoy bolezn'yu serdca s hronicheskoy serdechnoy nedostatochnost'yu i perenesennym COVID-19 // Medicinskiy vestnik MVD. – 2023 – 3 (124). – C. 37-41.
9. Barutaut M., Fournier P., Peacock W.F. et al. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heartfailur//ActaCardiol.–2020–75(8).– P.739–747.Doi:https://doi.org/10.1080/00015385.2019.1669847
10. Dong G., Chen H., Zhang H. et al. Long-Term and Short-Term Prognostic Value of Circulatin Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis // Cardiology. – 2021 – 146 (4). – P. 433–440. Doi:https://doi.org/10.1159/000509660
11. Chen W.W., Jiang J., Gao J. et al. Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: a systematic review and meta-analysis // Clin Cardiol. – 2023 – 46 (3). – P. 296-303.
12. Ovchinnikov A.G., T.I. Aref'eva, Potehina A.V. i dr. Molekulyarnye i kletochnye mehanizmy, associirovannye s mikrososudistym vospaleniem v patogeneze serdechnoy nedostatochnosti s sohranennoy frakciey vybrosa // Acta Naturae. – 2020 – 12(2). – C. 40–51.
13. Paulus W.J., Zile M.R. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited // Circulation Research. – 2021 – 128 (10). – P. 1451– 1467
14. Awad K., Zaki M.M., Mohammed M. et al. Lipid and blood pressure meta-analysis collaboration group. Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials // Mayo Clinic Proceedings. – 2022 – 97(10). – P. 1808–1823.
15. Zile M.R., O'Meara E., Claggett B. et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF // J Am Coll Cardiol. – 2019 – 73(7). – P. 795–806.
16. Tsutsui H., Momomura S.I., Saito Y. et al. Efficacy and safety of sacubitril/valsartan in japanese patients with chronic heart failure and reduced ejection fraction – results from the PARALLEL-HF study // Circ J. – 2021 – 85(5). – P. 584–594.
17. Anand I.S., Rector T.S., Kuskowski M. et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial // Circ Heart Fail. – 2014 – 7(3). – P. 418–426.
18. Mapelli M., Mattavelli I., Salvioni E. et al. Looking into the kinetics of NT-proBNP and sST2 changes in patients with heart failure treated with sacubitril/valsartan: a hint to different therapeutic pathways // Drugs RD. – 2023 – 23(4). – P. 397–402.
19. Pieske B., Wachter R., Shah S.J. et al. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial // JAMA. – 2021 – 326 (19). – P. 1919–1929.
